A bispecific antibody prolongs survival in XXXX bearing lung metastases of syngeneic @entity420 .

@entity19 @entity5168 @entity420 @entity5
In the present study we tested whether T cells retargeted with a bispecific antibody (bsAb) could block the growth of lung metastases of syngeneic @entity420 in immunocompetent @entity19 . BALB/c @entity19 were injected i.v. with @entity5 and i.p. with a genetically engineered bispecific F(ab')2 [bs(Fab')2] having specificity for @entity19 @entity5168 epsilon chain and for the gp52 @entity19 @entity5 viral glycoprotein, which is expressed on the @entity5 cells. The bs(Fab')2 was physically stable in blood and serum, was removed from the body with a half-time of 12-15 h, and accumulated in lymphoid tissue where it bound to T cells. We show that treatment of @entity5 bearing @entity19 with the bs(Fab')2 significantly prolonged their survival relative to untreated controls. Two other genetically engineered bs(Fab')2s having specificity for @entity19 @entity5168 epsilon chain and irrelevant antigens did not inhibit @entity5 growth. In addition, survival was not affected by bsAb therapy using a variant @entity5 cell line that expressed low levels of the gp52 target antigen. Inhibition of @entity5 growth was even more evident by histologic analysis. Treatment with the relevant bs(Fab')2 resulted in a marked @entity5 burden in lung sections taken on days 7, 9 and 11. This is the first report demonstrating that a bsAb can inhibit the growth of syngeneic solid @entity5 metastases in @entity19 without addition of T cell activators.
